Welcome to our dedicated page for Nuwellis news (Ticker: NUWE), a resource for investors and traders seeking the latest updates and insights on Nuwellis stock.
Nuwellis Inc (NUWE) is a leader in developing medical devices for fluid overload management and renal monitoring. This page serves as the definitive source for verified news and official announcements about the company’s innovations in critical care technology.
Access real-time updates on Aquadex SmartFlow System deployments, RenalSense Clarity RMS clinical validations, and strategic partnerships. Investors and healthcare professionals will find essential information about regulatory milestones, research findings, and operational developments directly impacting patient care standards.
Our curated collection includes earnings reports, product launch details, and peer-reviewed study outcomes. All content is rigorously verified to ensure accuracy while maintaining accessibility for both medical experts and general investors.
Bookmark this page for streamlined access to NUWE’s latest advancements in ultrafiltration therapy and kidney function monitoring technologies. Return regularly to stay informed about developments shaping the future of fluid management solutions.
Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company, is set to release its Q1 2023 financial results on May 9, 2023. The company will hold a conference call and webcast at 9:00 AM ET to discuss the financial results and provide a general business overview. Investors can access the live webcast on Nuwellis' Investors page or by calling the designated numbers provided for U.S. and international participants.
Nuwellis specializes in treating fluid overload issues with its Aquadex SmartFlow® system, aimed at transforming the lives of affected patients. This system is designed for use in both outpatient and inpatient settings under physician supervision.
Nuwellis, Inc. (Nasdaq: NUWE) recently announced a peer-reviewed publication supporting ultrafiltration as a viable treatment for acute decompensated heart failure (ADHF), particularly for patients unresponsive to diuretics. The publication, featured in Cardiorenal Medicine Journal, reviewed data from seven trials involving 771 patients, highlighting ultrafiltration's advantages in efficient fluid removal without harming renal function. This method could reduce hospital readmissions and alleviate healthcare costs associated with ADHF. Nuwellis aims to establish ultrafiltration as the standard of care through increased awareness and clinical evidence.
Nuwellis, Inc. (Nasdaq: NUWE) announced that the Company’s independent directors approved equity awards on February 23, 2023, under the 2021 Inducement Plan. These awards were granted as material inducements for six new hires. The equity awards consist of options to purchase a total of 2,514 shares at an exercise price of $8.27 per share, equal to the closing stock price on the grant date. The options have a ten-year term and vest over four years, with 25% vesting after one year and the remainder vesting monthly, contingent on ongoing employment.
Nuwellis focuses on the Aquadex SmartFlow system for treating fluid overload in patients.
Nuwellis, Inc. (NASDAQ: NUWE) reported a 42% increase in Q4 revenue, reaching $2.3 million, while full-year revenue grew by 8% to $8.5 million for 2022. The company achieved a gross margin of 56.9% in Q4, up 250 basis points year-over-year. Key segments included Pediatrics (92% growth), Heart Failure (47% growth), and Critical Care (24% growth). Nuwellis entered an exclusive licensing agreement for the Selective Cytopheretic Device to treat pediatric Acute Kidney Injury. Peer-reviewed data demonstrated significant improvements in hospitalizations related to heart failure and kidney replacement therapy survival rates. The company ended 2022 with $18.3 million in cash.
FAQ
What is the current stock price of Nuwellis (NUWE)?
What is the market cap of Nuwellis (NUWE)?
